WHAT IS CLAIMED IS:

1. A composition comprising a hepatic therapeutic amount of a hepatic pharmaceutical active having:

from about 25 to about 35% of one or more acridone compounds;

from about 15 to about 25% of one or more xanthone compounds;

from about 35 to about 45% of one or more thioxathone compounds;

from about 1 to about 10% of one or more tocotrienol compounds; and

from about 1 to about 10% of one or more oleanolic triterpenoid compounds.


2. The composition of claim 1, which further comprises a pharmaceutically acceptable carrier.

3. The composition of claim 1, wherein the hepatic therapeutic active has, by weight of the hepatic therapeutic active: from about 28 to about 32% of one or more acridone compounds; from about 18 to about 22% of one or more xanthone compounds; from about 38 to about 42% of one or more thioxathone compounds; from about 3 to about 7% of one or more tocotrienol compounds; and from about 3 to about 7% of one or more oleanolic triterpenoid compounds.

4. The composition of claim 1, wherein the hepatic therapeutic active comprises one or more *Cratoxylum cochinchinense* extracts comprising from about 28 to about 32% of acridone, from about 18 to about 22% of xanthone, from about 38 to about 42% of thioxanthone, from about 3 to about 7% of delta-tocotrienol, and from about 3 to about 7% of 3-hydroxy-23-sulfoxy-olean-12-en-28-oic acid.

5. The composition of claim 1, wherein the hepatic therapeutic active comprises a synthesized blend of the acridone compounds, xanthone compounds, thioxanthone compounds, tocotrienol compounds, and the oleanolic triterpenoid compounds.

6. The composition of claim 1, wherein the acridone compounds having the following general formula I.




I

wherein each of the R_{11}, R_{12}, R_{13}, R_{14}, R_{15}, R_{16}, R_{17}, or R_{18} groups are separately an H, hydroxy, halo, amino, sulfoxy, or aliphatic group; and wherein the R_{19} group is an H or aliphatic group.

7. The composition of claim 6, wherein the acridone compounds comprise one or more of: acridone or acridone acetic acid.

8. The composition of claim 1, wherein the xanthone compounds have the following general formula II:




II

wherein each of the R_{21}, R_{22}, R_{23}, R_{24}, R_{25}, R_{26}, R_{27}, or R_{28} groups are separately an H, hydroxy, halo, amino, sulfoxy, or aliphatic group.

9. The composition of claim 8, wherein the xanthone compounds comprise one or more of: xanthone; 5-O-methylcelebixanthone; celebixanthone; 1,3,7-trihydroxy-2,4-di(3-methylbut-2-enyl)xanthone; cochinchinone A; alpha-mangostin; beta-mangostin; or cochinchinone.

10. The composition of claim 1, wherein the thioxanthone compounds have the following general formula III:




III

wherein each of the R_{31}, R_{32}, R_{33}, R_{34}, R_{35}, R_{36}, R_{37}, or R_{38} groups are separately an H, hydroxy, halo, amino, sulfoxy, or aliphatic group.

11. The composition of claim 10, wherein the thioxanthone compounds comprise one or more of: thioxanthone; or the thio analogs of 5-O-methylcelebixanthone, celebixanthone, 1,3,7-trihihydroxy-2,4-di(3-methylbut-2-enyl)xanthone, cochinchinone A, alpha-mangostin, beta-mangostin, and cochinchinone.

12. The composition of claim 1, wherein the tocotrienol compounds have the following general formula IV:




IV

wherein each of the R_{41}, R_{42}, R_{43}, and R_{44} groups are separately an H, hydroxy, halo, amino, sulfoxy, or aliphatic group.


13. The composition of claim 12, wherein the tocotrienol compounds comprise one or more of: alpha-tocotrienol; beta-tocotrienol; gamma-tocotrienol; or delta-tocotrienol.

14. The composition of claim 1, wherein the oleanolic triterpenoid compounds are one or more of: oleanolic acid; derivatives of oleanolic acid having the following general formula V:



V

wherein M_1 is H or an alkali metal; wherein M_2 is H, an alkali metal, an aliphatic group, or an aromatic group; and wherein each of R_{51}, R_{52}, R_{53}, R_{54}, R_{55}, or R_{56}, are separately an H, hydroxy, halo, amino, sulfoxy, or aliphatic group; or derivative of oleanolic acid having the following general formula VI:



VI

wherein M_3 is H, an alkali metal (*e.g.*, sodium, potassium, *etc.*), an aliphatic group, or an aromatic group; and wherein each of R_{61}, R_{62}, R_{63}, R_{64}, R_{65}, R_{66}, or R_{67}, separately are an H, hydroxy, halo, amino, sulfoxy, or aliphatic group..

15. The composition of claim 14, wherein the oleanolic triterpenoid compounds comprise one or more of: 3-hydroxy-23-sulfoxy-olean-12-en-28-oic acid; 2-cyano-3,12-dioxooleana-1,9 (11)-dien-28-oic (CDDO); the respective methyl ester of CDDO; or the respective imidazolide of CDDO.

16. The composition of claim 1, which is in the form of an orally ingestable single unit dosage composition and wherein the composition comprises from about 250 to about 750 mg. of the hepatic therapeutic active.

17. The composition of claim 16, wherein the composition comprises from about 450 to about 550 mg. of the hepatic therapeutic active.

18. The composition of claim 1, wherein the hepatic therapeutic active comprises: acridone; xanthone; thioxanthone; delta-tocotrienol; and 3-hydroxy-23-sulfoxy-olean-12-en-28-oic acid.

19. A method comprising the following steps:

(a) providing a hepatic therapeutic active having, by weight of the hepatic therapeutic active: from about 25 to about 35% of one or more acridone compounds; from about 15 to about 25% of one or more xanthone compounds; from about 35 to about 45% of one or more thioxathone compounds; from about 1 to about 10% of one or more tocotrienol compounds; and from about 1 to about 10% of one or more oleanolic triterpenoid compounds; and

(b) administering a hepatic therapeutic amount of the hepatic therapeutic active to a patient afflicted with a liver disease.

20. The method of claim 19, wherein step (b) is carried out by orally administering to a human patient the hepatic therapeutic active of step (a).

21. The method of claim 19, wherein the patient of step (b) is a human patient afflicted with one or more of the following liver diseases: hepatitis B; hepatitis C; cirrhosis; liver poisoning; hepatocellular carcinoma (HCC); a co-infection of HIV and hepatitis B; or a co-infection of HIV and hepatitis C.

22. The method of claim 21, wherein the human patient of step (b) is afflicted with hepatitis B.

23. The method of claim 21, wherein the human patient of step (b) is afflicted with hepatitis C.

24. The method of claim 21, wherein the human patient of step (b) is afflicted with hepatocellular carcinoma (HCC).

25. The method of claim 21, wherein the human patient of step (b) is afflicted with a co-infection of HIV and hepatitis B, or a co-infection of HIV and hepatitis C.

26. The method of claim 19, wherein the patient of step (b) is a human patient afflicted with one or more of chronic hepatitis B or chronic hepatitis C, and wherein step (b) is carried out by administering from about 2000 to about 4000 mg. per day of the hepatic therapeutic active to the human patient for a period of at least about 30 days,.

27. The method of claim 26, wherein step (b) is carried out by administering from about 2500 to about 3500 mg. per day of the hepatic therapeutic active to the human patient for a period of from about 30 to about 60 days.

28. The method of claim 19, wherein the patient of step (b) is a human patient afflicted with hepatocellular carcinoma (HCC) and wherein step (b) is carried out by administering from about 3500 to about 5500 mg. per day of the hepatic therapeutic active to the human patient for a period of at least about 30 days,.

29. The method of claim 28, wherein step (b) is carried out by administering from about 4000 to about 5000 mg. per day of the hepatic therapeutic active to the human patient for a period of from about 30 to about 60 days.

30. The method of claim 19, wherein the hepatic therapeutic active of step (a) is administered to the patient in step (b) in combination with a pharmaceutically acceptable carrier.

31. The method of claim 19, wherein the hepatic therapeutic active of step (a) comprises one or more *Cratoxylum cochinchinense* extracts comprising from about 28 to about 32% of acridone, from about 18 to about 22% of xanthone, from about 38 to about 42% of thioxanthone, from about 3 to about 7% of delta-tocotrienol, and from about 3 to about 7% of 3-hydroxy-23-sulfoxy-olean-12-en-28-oic acid.

32. The method of claim 19, wherein step (b) is carried out by administering a hepatic therapeutic active comprising: acridone; xanthone; thioxanthone; delta-tocotrienol; and 3-hydroxy-23-sulfoxy-olean-12-en-28-oic acid.

33. A method comprising the following steps:

(a) providing a hepatic therapeutic active having, by weight of the hepatic therapeutic active: from about 25 to about 35% of one or more acridone compounds; from about 15 to about 25% of one or more xanthone compounds; from about 35 to about 45% of one or more thioxathone compounds; from about 1 to about 10% of one or more tocotrienol compounds; and from about 1 to about 10% of one or more oleanolic triterpenoid compounds; and

(b) administering a therapeutic amount of the hepatic therapeutic active to a patient afflicted with a CA19-9 cancer.

34. The method of claim 33, wherein the patient of step (b) is a human patient afflicted with one or more of: liver cancer, gastric cancer, pancreatic cancer, colorectal cancer bile duct cancer, esophageal cancer, or gastro intestinal tract cancer.

35. A method comprising the following steps:

(a) providing a hepatic therapeutic active having, by weight of the hepatic therapeutic active: from about 25 to about 35% of one or more acridone compounds; from about 15 to about 25% of one or more xanthone compounds; from about 35 to about 45% of one or more thioxathone compounds; from about 1 to about 10% of one or more tocotrienol compounds; and from about 1 to about 10% of one or more oleanolic triterpenoid compounds; and

(b) administering a liver health maintenance amount of the hepatic therapeutic active to a human in need of liver health maintenance.

36. The method of claim 35, wherein the hepatic therapeutic active of step (a) comprises one or more *Cratoxylum cochinchinense* extracts comprising from about 28 to about 32% of acridone, from about 18 to about 22% of xanthone, from about 38 to about 42% of thioxanthone, from about 3 to about 7% of delta-tocotrienol, and from about 3 to about 7% of 3-hydroxy-23-sulfoxy-olean-12-en-28-oic acid.

WHAT IS CLAIMED IS:

1. A composition comprising a hepatic therapeutic amount of a hepatic pharmaceutical active having:

from about 25 to about 35% of one or more acridone compounds;

from about 15 to about 25% of one or more xanthone compounds;

from about 35 to about 45% of one or more thioxathone compounds;

from about 1 to about 10% of one or more tocotrienol compounds; and

from about 1 to about 10% of one or more oleanolic triterpenoid compounds.


2. The composition of claim 1, which further comprises a pharmaceutically acceptable carrier.

3. The composition of claim 1, wherein the hepatic therapeutic active has, by weight of the hepatic therapeutic active: from about 28 to about 32% of one or more acridone compounds; from about 18 to about 22% of one or more xanthone compounds; from about 38 to about 42% of one or more thioxathone compounds; from about 3 to about 7% of one or more tocotrienol compounds; and from about 3 to about 7% of one or more oleanolic triterpenoid compounds.

4. The composition of claim 1, wherein the hepatic therapeutic active comprises one or more *Cratoxylum cochinchinense* extracts comprising from about 28 to about 32% of acridone, from about 18 to about 22% of xanthone, from about 38 to about 42% of thioxanthone, from about 3 to about 7% of delta-tocotrienol, and from about 3 to about 7% of 3-hydroxy-23-sulfoxy-olean-12-en-28-oic acid.

5. The composition of claim 1, wherein the hepatic therapeutic active comprises a synthesized blend of the acridone compounds, xanthone compounds, thioxanthone compounds, tocotrienol compounds, and the oleanolic triterpenoid compounds.

6. The composition of claim 1, wherein the acridone compounds having the following general formula I.




I

wherein each of the R_{11}, R_{12}, R_{13}, R_{14}, R_{15}, R_{16}, R_{17}, or R_{18} groups are separately an H, hydroxy, halo, amino, sulfoxy, or aliphatic group; and wherein the R_{19} group is an H or aliphatic group.

7. The composition of claim 6, wherein the acridone compounds comprise one or more of: acridone or acridone acetic acid.

8. The composition of claim 1, wherein the xanthone compounds have the following general formula II:




II

wherein each of the R_{21}, R_{22}, R_{23}, R_{24}, R_{25}, R_{26}, R_{27}, or R_{28} groups are separately an H, hydroxy, halo, amino, sulfoxy, or aliphatic group.

9. The composition of claim 8, wherein the xanthone compounds comprise one or more of: xanthone; 5-O-methylcelebixanthone; celebixanthone; 1,3,7-trihydroxy-2,4-di(3-methylbut-2-enyl)xanthone; cochinchinone A; alpha-mangostin; beta-mangostin; or cochinchinone.

10. The composition of claim 1, wherein the thioxanthone compounds have the following general formula III:




III

wherein each of the R_{31}, R_{32}, R_{33}, R_{34}, R_{35}, R_{36}, R_{37}, or R_{38} groups are separately an H, hydroxy, halo, amino, sulfoxy, or aliphatic group.

11. The composition of claim 10, wherein the thioxanthone compounds comprise one or more of: thioxanthone; or the thio analogs of 5-O-methylcelebixanthone, celebixanthone, 1,3,7-trihihydroxy-2,4-di(3-methylbut-2-enyl)xanthone, cochinchinone A, alpha-mangostin, beta-mangostin, and cochinchinone.

12. The composition of claim 1, wherein the tocotrienol compounds have the following general formula IV:




IV

wherein each of the R_{41}, R_{42}, R_{43}, and R_{44} groups are separately an H, hydroxy, halo, amino, sulfoxy, or aliphatic group.


13. The composition of claim 12, wherein the tocotrienol compounds comprise one or more of: alpha-tocotrienol; beta-tocotrienol; gamma-tocotrienol; or delta-tocotrienol.

14. The composition of claim 1, wherein the oleanolic triterpenoid compounds are one or more of: oleanolic acid; derivatives of oleanolic acid having the following general formula V:



V

wherein M_1 is H or an alkali metal; wherein M_2 is H, an alkali metal, an aliphatic group, or an aromatic group; and wherein each of R_{51}, R_{52}, R_{53}, R_{54}, R_{55}, or R_{56}, are separately an H, hydroxy, halo, amino, sulfoxy, or aliphatic group; or derivative of oleanolic acid having the following general formula VI:



VI

wherein M_3 is H, an alkali metal (*e.g.*, sodium, potassium, *etc.*), an aliphatic group, or an aromatic group; and wherein each of R_{61}, R_{62}, R_{63}, R_{64}, R_{65}, R_{66}, or R_{67}, separately are an H, hydroxy, halo, amino, sulfoxy, or aliphatic group..

15. The composition of claim 14, wherein the oleanolic triterpenoid compounds comprise one or more of: 3-hydroxy-23-sulfoxy-olean-12-en-28-oic acid; 2-cyano-3,12-dioxooleana-1,9 (11)-dien-28-oic (CDDO); the respective methyl ester of CDDO; or the respective imidazolide of CDDO.

16. The composition of claim 1, which is in the form of an orally ingestable single unit dosage composition and wherein the composition comprises from about 250 to about 750 mg. of the hepatic therapeutic active.

17. The composition of claim 16, wherein the composition comprises from about 450 to about 550 mg. of the hepatic therapeutic active.

18. The composition of claim 1, wherein the hepatic therapeutic active comprises: acridone; xanthone; thioxanthone; delta-tocotrienol; and 3-hydroxy-23-sulfoxy-olean-12-en-28-oic acid.